Pegylated Interferon Lambda for Treatment of COVID-19 Infection

Summary

A randomized, open-label, 2 arm, pilot trial of Lambda 180 mcg administered subcutaneously once weekly, for up to two weeks (2 injections at most), in addition to standard supportive care, compared to standard supportive care alone, in a population of COVID-19 infected patients. patients will be randomized according to 1:1 ratio to one of the 2 trial arms: Lambda 180 mcg S.C + standard care (intervention arm) or standard care only (control arm).

Timeline

Start

2020-04-07

Primary completion

2023-02-16

Completion

2023-02-16

Drugs

Indications